Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3017147 | 0.83 | L3MBTL1 (0.35) | PIK3CGL3MBTL1LMNANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3013084 | 0.82 | L3MBTL1 (0.34) | PIK3CGL3MBTL1LMNANPC1RAB9A | |
| SCHEMBL3021418 | 0.75 | HPGD (0.33) | PIK3CGL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16432426 | 0.72 | — | — | |
| SCHEMBL1202772 | 0.71 | L3MBTL1 (0.41) | PIK3CGL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4760420 | 0.71 | HTT (0.56) | L3MBTL1LMNASMN1; SMN2HTT | |
| SCHEMBL7886825 | 0.71 | KDM4E (0.35) | PIK3CGL3MBTL1LMNANPC1RAB9A | |
| SCHEMBL20542099 | 0.69 | NUDT1 (0.30) | — | |
| SCHEMBL16009628 | 0.68 | KMT2A (0.39) | PIK3CGLMNASMN1; SMN2HTT | |
| SCHEMBL3028224 | 0.68 | SYK (0.31) | L3MBTL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025121436-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL USE CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学クロップ＆ライフソリューション株式会社 | 2025-06-12 | — | — | WO | disclosed |
| US-20250002507-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-01-02 | — | — | US | disclosed |
| WO-2023064584-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2964230-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138692-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138692-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-11 | — | — | US | disclosed |
| EP-0562440-B1 | Imidazopyridazines as antiasthmatics | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0548923-B1 | Antiallergic, antiinflammatory and anti-PAF pyridazine compounds | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-07-08 | — | — | EP | disclosed |
| US-5491145-A | ANTIASTHMA, ANTI-PLATELET ACTIVATING FACTOR BRONCHOCONSTRICTION-INHIBITING AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-13 | — | — | US | disclosed |
| US-5369104-A | Antiasthmatic agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-29 | — | — | US | disclosed |
| EP-0562440-A1 | Imidazopyridazines as antiasthmatics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0548923-A2 | Antiallergic, antiinflammatory and anti-PAF pyridazine compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | PIK3CG 401/4885L3MBTL1 2389/4885LMNA 1218/4885 |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | PIK3CG 401/4885L3MBTL1 2389/4885LMNA 1218/4885 |
| US-20250002507-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM4, CHRM1, CHRM2 | PIK3CG 3211/4885L3MBTL1 294/4885LMNA 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.